Aeterna Zentaris has submitted an NDA to the FDA for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase III data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency (AGHD), with accuracy comparable to available intravenous and intramuscular testing procedures. Macimorelin acetate is a novel orally-active small molecule that stimulates the secretion of growth horm...